Deborah Card

Companion diagnostics for pembrolizumab in patients with dMMR/MSI-H tumors

Pembrolizumab is approved in the US for unresectable or metastatic mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) solid tumors that progressed after prior treatment and with no satisfactory alternative treatment options. As part of post-marketing commitm...